Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
Although the Trump administration's GLOBE model shrank from an anticipated $11.9 billion in savings to roughly $440 million impacting only a handful of companies, its true danger to biopharma is precedent. Pharma agreements endorsing foreign prices as valid benchmarks for U.S. reimbursement give policymakers enduring leverage to justify international reference pricing and direct executive price negotiations in future Medicare programs.
Related Insights
Initial panic over the MFN drug pricing scheme was based on pegging U.S. prices to the lowest in the industrialized world. The actual proposal is far less drastic, targeting the second-lowest price among a small cohort of high-income nations (G7 plus Denmark and Switzerland), a significantly less onerous benchmark.
The argument against adopting lower foreign drug prices is framed as a national security imperative. Proponents argue that such price controls would slash U.S. R&D investment, allowing China to dominate the bio-pharma sector and potentially weaponize future drug supply chains in a crisis.
The administration is leveraging the U.S.'s market power to demand "most favored nation" pricing from pharmaceutical companies. This forces them to offer drugs at the lowest price available in any other developed nation, slashing costs for American consumers.
The Trump administration's Most Favored Nation (MFN) drug deals set a precedent for ad hoc negotiations. If Democrats gain power and expose these deals as lenient, it could provoke Congress to impose even more stringent, legislated price controls, ultimately harming the industry more than the current agreements.
By voluntarily agreeing to a watered-down version of a 'most favored nation' pricing system, pharmaceutical companies have inadvertently set a precedent. This makes it harder for them to argue against more stringent, codified pricing regulations from future administrations, as they can no longer claim it's a 'red line' they cannot cross.
The Most Favored Nation (MFN) policy forces a difficult choice: launch early in Europe and risk a lower US reference price, or delay the European launch to protect US revenue, slowing patient access. This dilemma upends traditional global launch strategies, creating commercial, ethical, and operational problems for pharma companies.
The US Most Favored Nation (MFN) drug pricing policy includes a creative revenue-sharing provision. If a company like Pfizer raises prices in Europe, it must share some of that increased revenue with the US government. This incentivizes raising ex-US prices to equalize the global market, rather than simply cutting prices domestically.
MFN's pressure on global pricing will change how innovation is valued. Truly disruptive drugs may command higher prices ex-US, while incremental "me-too" drugs in crowded classes will not. This will force pharma companies to shift R&D investment away from iterative improvements and toward therapies with radical treatment-disrupting potential.
The agreement between the Trump administration and pharma on Mounjaro/Ozempic pricing ratified a new "large market, medium price" benchmark. This fundamentally expands the industry's total addressable market beyond the old "small market, high price" model for rare diseases, suggesting a major long-term growth driver.
New "voluntary" CMS programs, like BALANCE for obesity drugs, are creating a framework for Most Favored Nation (MFN) style pricing in the US. They allow manufacturers to trade lower, internationally-referenced prices for higher volumes, fundamentally altering the US pricing landscape from the inside out.
